[1]曹若彤,沈家林,赵唯含.“扶正-通络-解毒”法干预大鼠毒瘀交阻型胃癌前病变作用机制[J].陕西中医,2025,46(11):1449-1453.[doi:DOI:10.3969/j.issn.1000-7369.2025.11.002]
　CAO Ruotong,SHEN Jialin,ZHAO Weihan.Mechanism of action of Fuzheng-Tongluo-Jiedu method in intervening precancerous lesions of gastric cancer in rats with toxin-stasis intermingling syndrome[J].,2025,46(11):1449-1453.[doi:DOI:10.3969/j.issn.1000-7369.2025.11.002]
点击复制

“扶正-通络-解毒”法干预大鼠毒瘀交阻型胃癌前病变作用机制
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年11期
页码:
1449-1453
栏目:
基础研究
出版日期:
2025-11-05

文章信息/Info

Title:
Mechanism of action of Fuzheng-Tongluo-Jiedu method in intervening precancerous lesions of gastric cancer in rats with toxin-stasis intermingling syndrome
作者:
曹若彤1; 沈家林1; 赵唯含2
（1.陕西中医药大学，陕西 咸阳 712046；2.陕西中医药大学附属医院，陕西 咸阳 712021)
Author(s):
CAO Ruotong1; SHEN Jialin1; ZHAO Weihan2
(1.Shaanxi University of Chinese Medicine,Xianyang 712046，China；2.The Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712021，China)
关键词:
胃癌前病变; 上皮间充质转化; 健脾养阴祛瘀方; 白细胞介素-6; Janus 激酶-2; 信号转导和转录激活因子3; 炎症微环境
Keywords:
Precancerous lesions of gastric cancer; Epithelial-mesenchymal transition; Jianpi Yangyin Quyu formula; Interleukin-6;  Janus kinase-2;  Signal transducer and activator of transcription 3; Inflammatory microenvironment
分类号:
R 289
DOI:
DOI:10.3969/j.issn.1000-7369.2025.11.002
文献标志码:
A
摘要:
目的：探讨健脾养阴祛瘀方对胃癌前病变（PLGC）大鼠IL-6/JAK2/STAT3通路调控胃黏膜上皮-间质转化（EMT）的作用机制。方法：58只SD大鼠随机分为空白对照组和模型建立组，采用多因素复合方法建立PLGC大鼠模型。造模成功后将模型建立组分为模型组、叶酸组及健脾养阴祛瘀方高、中、低剂量组，每组8只。治疗8周后，采用HE染色观察胃组织病理变化，ELISA检测TNF-α、IL-6水平，qPCR检测JAK2、STAT3的mRNA表达；Western Blot检测JAK2/p-JAK2和STAT3/p-STAT3蛋白表达；免疫组化检测C-myc蛋白表达。结果：健脾养阴祛瘀方能改善胃黏膜萎缩、肠化生、异型增生等病理表现，下调IL-6、TNF-α、JAK2、p-JAK2、STAT3、p-STAT3和C-myc表达（P＜0.05），其中健脾养阴祛瘀方高剂量组效果较好。结论：健脾养阴祛瘀方通过改善炎症微环境，抑制JAK2/STAT3通路活化和C-myc表达，抑制EMT进程，缓解PLGC。
Abstract:
Objective:To investigate mechanism by Jianpi Yangyin Quyu formula regulates gastric mucosal epithelial-mesenchymal transition (EMT) via the IL-6/JAK2/STAT3 pathway in rats with precancerous lesions of gastric cancer (PLGC).Methods:A total of 58 SD rats were randomly divided into blank control group and model establishment group.The PLGC rat model was induced using a multi-factor composite method.After successful modeling,the model establishment group were further divided into model group,folic acid group,and high-dose,medium-dose and low-dose Jianpi Yangyin Quyu formula formula groups (n=8 per group).After 8 weeks of treatment,HE staining was used to observe pathological changes in gastric tissue.ELISA was performed to detect TNF-α and IL-6 levels.qPCR was used to measure mRNA expression of JAK2 and STAT3.Western blotting was employed to assess the protein expression of JAK2/p-JAK2 and STAT3/p-STAT3.Immunohistochemistry was applied to evaluate C-myc protein expression.Results:Jianpi Yangyin Quyu formula formula significantly ameliorated pathological manifestations,including gastric mucosal atrophy,intestinal metaplasia,and dysplasia.It down regulated the expression of IL-6,TNF-α,JAK2,p-JAK2,STAT3,p-STAT3,and C-myc (P＜0.05),with the high-dose Jianpi Yangyin Quyu formula group exhibiting the most pronounced effects.Conclusion:Jianpi Yangyin Quyu formula formula alleviates PLGC by improving inflammatory microenvironment,inhibiting the activation of the JAK2/STAT3 pathway and C-myc expression,and suppressing the EMT process.

参考文献/References:

[1]CORREA P,PIAZUELO M B.The gastric precancerous cascade[J].J Dig Dis,2012,13(1):2-9.
[2]周鹤翔,陈希琦,周永坤.中医药调控胃癌上皮间质转化相关信号通路的研究进展[J].中医临床研究,2023,15(23):108-113.
[3]万昱辰,刘粉叶.胃癌前病变中医病机与治疗机制研究进展[J].辽宁中医药大学学报,2022,24(8):44-48.
[4]SADRKHANLOO M,ENTEZARI M,OROUEI S,et al.STAT3-EMT axis in tumors:Modulation of cancer metastasis stemness and therapy response[J].Pharmacological Research,2022,182:106311.
[5]赵德敏,梁锦铃,高玖妹,等.中医药调控JAK2/STAT3信号通路治疗子宫内膜异位症研究进展[J].陕西中医,2025,46(4):568-571,576.
[6]ZHANG H,HUANG S,YE Z,et al.Yiqi Huayu Jiedu formula inhibits JAK2/STAT3-mediated partial EMT in treating chronic atrophic gastritis[J].Phytomedicine,2025,137(2):156356.
[7]王笑民.立足中医理论创新肿瘤诊疗[J].陕西中医,2025,46(7):867-869.
[8]沈家林,许雨晴,曹若彤,等.金果胃康胶囊对胃癌前病变模型大鼠胃黏膜ULK1/AMPK/mTOR信号通路的影响[J].陕西中医,2024,45(4):446-450.
[9]公艳霞,白敏,刘自由,等.基于IL-6/JAK2/STAT3通路探讨化瘀消痞汤对胃癌前病变大鼠胃黏膜损伤的作用及机制[J].中药新药与临床药理,2024,35(12):1827-1834.
[10]陈沛萍,黄凤玉,张昕卓,等.仁青芒觉对MNNG诱导的胃黏膜上皮细胞恶性转化的干预作用及机制[J].中国实验方剂学杂志,2025,31(8):69-77.
[11]黎敏航,马晓聪,唐燕,等.基于JAK2/STAT3信号通路探讨荔枝核总黄酮对HepG2增殖、迁移与侵袭的影响[J].中国实验方剂学杂志,2022,28(22):85-92.
[12]张俊立.癌相关成纤维细胞通过分泌IL-17A激活JAK2/STAT3信号通路促进胃癌细胞迁移和侵袭[D].郑州：郑州大学,2020.
[13]乔云凤.扶正消瘤方调控EMT机制抑制胃癌细胞侵袭、迁移的实验研究[D].济南：山东中医药大学,2023.
[14]WANG X,EICHHORN P J A,THIERY J P.TGF-β EMT and resistance to anti-cancer treatment[J].Semin Cancer Biol，2023，97（12）:1-11.
[15]LIU Z W,ZHANG Y M,ZHANG L Y,et al.Duality of interactions between TGF-β and TNF-α during tumor formation[J].Front Immunol，2022，5（1）:810286.
[16]CHEN Y,ZHU S,LIU T,et al.Epithelial cells activate fibroblasts to promote esophageal cancer development[J].Cancer Cell，2023，41(5):903-918.
[17]许倩倩.胃癌前病变核心基因鉴定及脐带间充质干细胞治疗效果和机制探究[D].济南：山东大学,2024.
[18]朱云峰.肿瘤相关成纤维细胞通过IL-6-JAK2/STAT3-TGM2信号通路促进胃癌细胞迁移、侵袭的机制研究[D].成都：四川大学,2023.
[19]JIN X,SHANG B,WANG J,et al.Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes[J].Cell Death Dis，2024，15(2):148.
[20]GUO X,SHEN X,YONG Z.MiR-101 protects against the cerebral I/R injury through regulating JAK2 /STAT3 signaling pathway[J].Neuropsychiatr Dis Treat,2021,17(8):2791-2802.
[21]HUANG B,LANG X,LI X.The role of IL-6/JAK2/STAT3 signaling pathway in cancers[J].Front Oncol,2022,(12):1023177.
[22]常玉平,谢琪,周腾腾,等.橙皮苷调节IL-6/JAK2/STAT3信号通路对大鼠肥胖症模型的降脂作用实验研究[J].陕西医学杂志,2025,54(6):759-764.
[23]屈杭帅,田雄,潘怡晓,等.CDK8通过JAK2/STAT3/EMT途径促进食管鳞状细胞癌的细胞增殖、迁移和侵袭（英文）[J].生物化学与生物物理进展,2024,51(12):3238-3252.
[24]LI Z,YANG Z,LIU W,et al.Disheveled3 enhanced EMT and cancer stem-like cells properties via Wnt/β-catenin/C-myc/SOX2 pathway in colorectal cancer[J].Journal of Translational Medicine,2023,21(1):302.
[25]欧慧萍,吴趋荟,袁多,等.桃红四物汤通过JAK2/STAT3信号通路对肺纤维化模型大鼠凋亡及EMT的影响[J].中国药理学通报,2023,39(8):1577-1583.
[26]孔思雅,党旖旎,张国新.叶酸预防慢性萎缩性胃炎癌变的研究进展[J].中华消化杂志,2020,40(1):66-68.

相似文献/References:

[1]蔺焕萍,王 峰,周晓燕,等.李守朝教授治疗胃癌前病变临证经验拾萃[J].陕西中医,2021,(1):103.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.028]
　LIN Huanping,WANG Feng,ZHOU Xiaoyan,et al.Professor LI Shouchao's experience in the treatment of precancerous lesions of gastric cancer[J].,2021,(11):103.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.028]
[2]刘颖初,汪红兵,王雅欣,等.基于“补气活血”理论探讨胃癌前病变的“炎癌转化”[J].陕西中医,2023,(12):1767.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.022]
　LIU Yingchu,WANG Hongbing,WANG Yaxin,et al.Discussion on “inflammatory and cancer transformation” of precancerous lesions of gastric cancer based on the theory of “invigorating qi and activating blood circulation”[J].,2023,(11):1767.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.022]
[3]宋 健,孟凯强,雷根平,等.名中医沈舒文使用动物类中药治疗胃癌前病变临床经验[J].陕西中医,2024,(2):256.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.024]
[4]沈家林,许雨晴,曹若彤,等.金果胃康胶囊对胃癌前病变模型大鼠胃黏膜ULK1/AMPK/mTOR信号通路的影响[J].陕西中医,2024,(4):446.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.003]
　SHEN Jialin,XU Yuqing,CAO Ruotong,et al.Effect of Jinguo Weikang capsule on ULK1/AMPK/mTOR signaling pathway in gastric mucosa of precancerous lesions of gastric cancer model rats[J].,2024,(11):446.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.003]
[5]张高来,闻新丽.基于联合辨证论治胃癌前病变临床思维与经验[J].陕西中医,2024,(8):1101.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.020]
[6]刘 桐,孙鹤员,唐 强,等.基于圆运动理论探析胃癌前病变的病机与治疗[J].陕西中医,2025,46(4):508.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.016]
　LIU Tong,SUN Heyuan,TANG Qiang,et al.Discussion of the pathogenesis and treatment of gastric precancerous lesions based on circular motion theory[J].,2025,46(11):508.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.016]
[7]薛永立,赵唯含,申佳林,等.基于Hedgehog信号通路探讨中药防治胃癌研究进展[J].陕西中医,2025,46(11):1581.[doi:DOI:10.3969/j.issn.1000-7369.2025.11.027]
　XUE Yongli,ZHAO Weihan,SHEN Jialin,et al.Research progress on prevention and treatment of gastric cancer by traditional Chinese medicine based on Hedgehog signaling pathway[J].,2025,46(11):1581.[doi:DOI:10.3969/j.issn.1000-7369.2025.11.027]

备注/Memo

备注/Memo:
国家自然科学基金资助青年项目(81804082)；陕西省自然科学基金资助项目(2023-JC-JB-667)；陕西省中医药管理局科研项目(SZY-KJCYC-2023-019)
更新日期/Last Update: 2025-11-04